Skip to main content
. 2008 Aug 8;8:227. doi: 10.1186/1471-2407-8-227

Figure 1.

Figure 1

HT-29 and Caco-2 viability assay. Untreated (NT); 10 nM EGF (E); 5 (Cx5) and 10 (Cx10) nmol/L cetuximab; (Gb) 1 μmol/L gefitinib; 5 or 10 nmol/L cetuximab plus 10 nM EGF (Cx5 + E or Cx10 + E); 1 μmol/L gefitinib plus 10 nM EGF (Gb + E). ANOVA One-way analysis of variance and Tukey's Multiple Comparison Test. Caco-2. NT vs: **E, ***Cx5, *Cx10, ***Gb, ***Cx5 + E, *Cx10 + E, **Gb + E. *p < 0.05, **p < 0.01, ***p < 0.001. Each point represents a mean of quadruplicate values for each sample ± SD.